Chang, Elaine http://orcid.org/0000-0001-6255-2853
Apolo, Andrea B. http://orcid.org/0000-0001-9409-1836
Bangs, Rick http://orcid.org/0000-0002-0706-8775
Chisolm, Stephanie http://orcid.org/0000-0002-6194-3163
Duddalwar, Vinay http://orcid.org/0000-0002-4808-5715
Efstathiou, Jason A.
Goldberg, Kirsten B. http://orcid.org/0000-0001-8659-1240
Hansel, Donna E. http://orcid.org/0000-0001-7860-4881
Kamat, Ashish M. http://orcid.org/0000-0003-3546-9928
Kluetz, Paul G.
Lerner, Seth P.
Plimack, Elizabeth
Prowell, Tatiana
Singh, Harpreet
Suzman, Daniel
Yu, Evan Y.
Zhang, Hui
Beaver, Julia A.
Pazdur, Richard
Weinstock, Chana
Galsky, Matthew D.
Article History
Accepted: 13 July 2021
First Online: 10 September 2021
Competing interests
: E.C., A.B.A., K.B.G., P.G.K., T.P., H.S., D.S., H.Z., J.A.B., R.P. and C.W. are employees of the US government. R.B. receives honoraria from SWOG, the National Cancer Institute, the NCRA Working Group on Clinical Trials Enrollment and Retention, the Patient Advocate Steering Committee, the Cancer Care Delivery Research Steering Committee; he serves on committees with the National Comprehensive Cancer Network, the Bladder Cancer Advocacy Network, Stand Up to Cancer, Bladder Cancer (Editorial Board). V.D. receives funding from Samsung Healthcare; he serves on the advisory board for Deeptek and is a consultant for Radmetrix. J.A.E. has served as a consultant for Blue Earth Diagnostics, Boston Scientific, AstraZeneca, Taris Biomedical; and on advisory boards for Merck, Roivant Pharma, Myovant Sciences, Janssen, Bayer Healthcare, Progenics, Genentech and EMD Serono. A.M.K. receives funding from Adolor, Bristol-Myers Squibb (BMS), FKD Industries, FerGene, Heat Biologics, Merck, Photocure, SWOG, NIH/GU SPORE, AIBCCR, holds a patent for Cytokine Predictors of Response to Intravesical Therapy; he serves/served as a consultant or on the advisory board for Abbott Molecular, Arquer Diagnostics, ArTara, Asieris, AstraZeneca, BioClin Therapeutics, Biological Dynamics, BMS, Cepheid, CG Oncology, Cold Genesys, H3 Biomedicine/Eisai, Engene, FerGene, Ferring, Imagin Medical, Janssen, MdDxHealth, Medac, Merck, Pfizer, Photocure, ProTara, Roviant, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, US Biotest, and is a board member of the International Bladder Cancer Group. S.P.L. receives honoraria from UroToday, holds a patent for a TCGA classifier, is involved in clinical trials sponsored by Endo, FKD, JBL, Genentech, SWOG, URoGen, Vaxiion and Viventia; he serves as a consultant or on the advisory board for Ferring, Genentech, Merck, Pfizer, QED, UroGen, Vaxiion, Verity. E.P. receives institutional funding from Astellas, AstraZeneca, BMS, Genentech, Merck, Peloton, Pfizer; she serves as a consultant for BMS, Genentech, Incyte, Janssen, Merck, AstraZeneca, Pfizer. E.Y.Y. receives institutional funding from Bayer, Blue Earth, Daiichi-Sankyo, Dendreon, Merck, Pharmacyclics, Seattle Genetics, Taiho; he serves as a consultant or on the advisory board for Bayer, Clovis, Merck. M.D.G. holds stock/ownership in Rappta Therapeutics, receives institutional funding from Janssen Oncology, Dendreon, Novartis, BMS, Merck, AstraZeneca, Genentech/Roche; he serves as a consultant for BioMotiv, Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics. His institution holds a patent in Methods and Compositions for Treating Cancer and Related Methods.